Indole and Benzoxazine Derivatives as mGluR2 Allosteric Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological tools targeting metabotropic glutamate receptors (mGluRs) primarily act as orthosteric ligands, activating multiple receptor subtypes and lacking selectivity, whereas there is a need for compounds that can selectively modulate mGluR2 through allosteric mechanisms to treat neurological and psychiatric disorders associated with glutamate dysfunction.
Innovation Solution
Development of novel indole and benzoxazine derivatives that act as positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (mGluR2), binding to an allosteric site within the seven transmembrane region, enhancing the receptor's response to glutamate or mGluR2 agonists without activating the receptor on their own.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If orthosteric ligands are used to activate mGluRs, then receptor activation is achieved, but selectivity among receptor subtypes is lost
Solution Approach 1:
The patent introduces allosteric modulators as intermediary compounds that bind to a distinct allosteric site on mGluR2 rather than the orthosteric site. These modulators enhance receptor activation indirectly by stabilizing active conformations or increasing glutamate affinity, achieving both reliable activation and subtype selectivity. The allosteric site serves as a mediator that allows selective modulation without cross-reactivity with other glutamate receptor subtypes.
Solution Approach 2:
The invention targets a specific local region (allosteric site) within the mGluR2 receptor structure, particularly in the transmembrane domain, rather than the conserved orthosteric binding site. This localized approach allows the modulators to interact with unique structural features of mGluR2, providing subtype selectivity while maintaining activation functionality.
2Adaptability or versatility
If allosteric modulators are developed for selective mGluR2 modulation, then receptor subtype selectivity is improved, but compound development complexity increases
Solution Approach 1:
The patent segments the receptor interaction into two distinct components: orthosteric glutamate binding and allosteric modulator binding. This segmentation allows independent optimization of selectivity through the allosteric component while maintaining activation through the orthosteric component. The modular nature of allosteric site targeting simplifies the development process by focusing on unique structural features rather than the highly conserved orthosteric site.
3Reliability
If positive allosteric modulators are used to enhance glutamate response, then therapeutic efficacy is improved, but potential for off-target effects increases
Solution Approach 1:
The allosteric modulator acts as an intermediary that enhances rather than directly activates the receptor. By requiring endogenous glutamate or orthosteric agonist presence for full effect, the system inherently reduces off-target activation. The modulator intermediates between the agonist and the receptor's full activation state, providing a safety mechanism against unintended effects.
Data Source
AI summary
The present invention relates to novel indole and benzoxazine derivatives which are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2") and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.